Skip to main content
Premium Trial:

Request an Annual Quote

AmberGen Receives Strategic Investment from Bruker

NEW YORK – Life science firm AmberGen said late Friday that it has received a strategic investment from Bruker.

Watertown, Massachusetts-based AmberGen has developed a set of imaging reagents for MALDI mass spectrometry-based immunohistochemistry. Called Miralys Spatial Biology Imaging Reagents, they use peptide code photocleavable mass tags to enable high levels of multiplexing (up to roughly 100 proteins per experiment) across fresh frozen and formalin-fixed paraffin-embedded tissue sections as large as 25 mm by 75 mm.

The Miralys reagents are currently in beta release.

"The MALDI-MS tissue imaging community has long expressed a desire to spatially map targeted proteins, together with glycans, lipids, drugs, and their metabolites, where MALDI has found widespread utility using a label-free approach," Michael Easterling, director of imaging for Bruker's life science mass spectrometry division, said in a statement. "The innovative photocleavable peptide code mass tag technology developed by AmberGen for labeling proteins of interest is a perfect combination for large field-of-view, multiomic, and multimodal spatial tissue biology applications."

“The Miralys MALDI-IHC platform provides the life sciences market with very high multiplexed, multiomic, and multimodal imaging capabilities for understanding the complex mechanisms of disease and response to pharmaceutical treatment," AmberGen Founder and Executive Chairman Kenneth Rothschild said in a statement. "This strategic investment by Bruker will accelerate the introduction of the Miralys spatial biology approach to a wide variety of researchers and catalyze progress in critical areas such as tissue pathology research and drug development."

The size of Bruker's strategic investment was not disclosed.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.